{"anticipatedPostingDate":"2029-05","denomUnitsSelected":"Participants","description":"Outcome data will be provided after the study is completed.","reportingStatus":"NOT_POSTED","timeFrame":"From the time of informed consent, for approximately 24 months (or earlier if the participants discontinues from the study), and through Safety Follow-up (28 days after the last dose)","title":"Frequency of Adverse Events (AEs)","type":"SECONDARY"}